HC Wainwright Has Negative Outlook of CTMX FY2026 Earnings

Key Points

• HC Wainwright has cut its FY2026 earnings per share estimate for CytomX Therapeutics from ($0.01) to ($0.02), maintaining a "Buy" rating with a target price of $5.00.
• CytomX Therapeutics recently reported earnings of $0.27 per share in its latest quarter, exceeding analyst estimates, and achieving a significant net margin of 34.04%.
• Despite the earnings forecast reduction, five analysts currently rate CytomX Therapeutics' stock as a "buy," with an average target price of $5.75.

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Analysts at HC Wainwright dropped their FY2026 earnings per share estimates for CytomX Therapeutics in a report issued on Monday, August 11th. HC Wainwright analyst M. Kapoor now forecasts that the biotechnology company will post earnings of ($0.02) per share for the year, down from their previous estimate of ($0.01). HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for CytomX Therapeutics' current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for CytomX Therapeutics' Q4 2026 earnings at ($0.01) EPS.

Several other brokerages have also recently issued reports on CTMX. Piper Sandler lifted their price objective on CytomX Therapeutics from $2.50 to $5.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. Oppenheimer started coverage on CytomX Therapeutics in a research report on Thursday, July 31st. They set an "outperform" rating and a $7.00 price target for the company. Wedbush reissued an "outperform" rating and set a $6.00 price target (up previously from $5.00) on shares of CytomX Therapeutics in a research report on Monday, May 12th. Finally, Wall Street Zen raised CytomX Therapeutics from a "hold" rating to a "buy" rating in a research report on Tuesday, May 13th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, CytomX Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $5.75.

CytomX Therapeutics Stock Performance

CTMX stock traded up $0.21 during midday trading on Wednesday, hitting $2.12. 7,605,815 shares of the stock were exchanged, compared to its average volume of 3,303,053. The stock's 50-day moving average price is $2.34 and its 200-day moving average price is $1.50. The stock has a market cap of $349.61 million, a price-to-earnings ratio of 3.79 and a beta of 2.13. CytomX Therapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $3.10.

Hedge Funds Weigh In On CytomX Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Assenagon Asset Management S.A. increased its position in CytomX Therapeutics by 1.2% during the second quarter. Assenagon Asset Management S.A. now owns 720,020 shares of the biotechnology company's stock worth $1,634,000 after buying an additional 8,566 shares in the last quarter. Aspire Growth Partners LLC grew its position in shares of CytomX Therapeutics by 10.8% in the second quarter. Aspire Growth Partners LLC now owns 102,254 shares of the biotechnology company's stock valued at $232,000 after purchasing an additional 10,000 shares during the period. Vanguard Personalized Indexing Management LLC grew its position in shares of CytomX Therapeutics by 63.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 28,966 shares of the biotechnology company's stock valued at $66,000 after purchasing an additional 11,258 shares during the period. Invesco Ltd. purchased a new stake in shares of CytomX Therapeutics in the second quarter valued at $32,000. Finally, Pursue Wealth Partners LLC purchased a new stake in shares of CytomX Therapeutics in the second quarter valued at $33,000. Hedge funds and other institutional investors own 67.77% of the company's stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.